Navigation Links
Nasal spray using body's immune system provides hope of cure for common cold
Date:6/23/2008

A nasal spray that mimics our own natural defense system may be the answer to beating the common cold, according to a report in the latest issue of the Society of Chemical Industry's (SCI) magazine, Chemistry & Industry, published today.

The spray, being produced by the Califormia based company Novabay, contains an analogue of N-Chlorotaurine (NCT), a compound produced by white blood cells when they are attacked. It works in a similar way to bleach in that it creates a chlorine cover around microorganisms such as bacteria, viruses and fungi, which kills them.

Ronald Eccles, director of the Common Cold Centre at Cardiff University hailed Novabay's approach as 'interesting and potentially useful'.

There is currently no treatment for the common cold but if talks between Novabay and the UK's NHS to set up clinical trials to test the spray's efficacy become a reality, it may only be a matter of time before a cure is on the horizon.

The spray has already proved effective against MRSA, achieving an 88% decolonisation rate in clinical trials.

And because the treatment would be based on our immune system, there would be no danger of growing resistance.

'Antibiotics are a dead end we are losing all of our effective antibiotics and we simply need something else,' says Novabay CEO Ron Najafi.

But Ronald Eccles urged caution saying; 'The next step is to see what happens when it is applied in the nose of patients. Many substances that work in vitro against viruses fail to work in clinical trials in patients.'


'/>"/>

Contact: Meral Nugent
meral.nugent@soci.org
020-759-81533
Society of Chemical Industry
Source:Eurekalert

Page: 1

Related medicine news :

1. Nasal Irrigation Can Help Fight Spring Allergies
2. Immune system kick-started in moist nasal lining in sinusitis, asthma and colds
3. Nasal Surgery Helps Ease Sleep Apnea Symptoms
4. Alcons PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
5. Researchers Pursuing Nasal Anthrax Vaccine
6. Nasal polyps from analgesics
7. Saline Nasal Wash Helps Kids Fight Colds, Flu
8. Protein Nasal Spray Revives Sleep-Deprived Monkeys
9. Saline Irrigation Eases Chronic Nasal Symptoms
10. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
11. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Raton (PRWEB) , ... September 19, 2017 , ... ... the El Naturalista brand, developed by ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. ... in Spain, and El Naturalista is a trusted, well-respected brand reliant on the ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... with the Davidson Fellows Scholarship on September 27 at a reception in Washington ... Technology, Engineering, Mathematics, Literature and Music. , “I am honored to be a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency nursing expertise, skill ... Emergency Nurse (CEN®) certification according to a large-scale study announced today by ... conducted by the Human Resources Research Organization (HumRRO) in late 2016 and early ...
(Date:9/18/2017)... Bangkok, Thailand (PRWEB) , ... September 19, 2017 ... ... in Asia Pacific’s protein ingredient market , expected to grow at the ... Frost & Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology: